Compare Indonesia Energy Corporation Limited (INDO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indonesia Energy Corporation Limited vs Neurocrine Biosciences Inc — how do they compare? Indonesia Energy Corporation Limited trades at $2.91 (market cap $44.93M), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 373× Indonesia Energy Corporation Limited's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| INDO | NBIX | |
|---|---|---|
Market Cap | $44.93M | $16.76B |
Sector | Energy | Health |
52-Week High | $6.74 | $185.50 |
52-Week Low | $2.49 | $123.10 |
Enterprise Value | $40.30M | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.80 with a slight 0.72% daily gain. The technical picture is bearish with moving averages signaling caution, while fundamentals show significant challenges with negative profit margins (-253.4%) and weak revenue of $2M in 2025. Recent news highlights operational progress with drilling commencement at the K-29 well. Analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook is speculative given deep losses, but drilling success could drive upside. Key risks include execution in exploration, sustained negative cash flow, and oil price volatility. The stock presents high-risk potential for investors betting on operational turnaround versus current financial distress.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
